StockNews.AI
NUWE
StockNews.AI
182 days

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

1. NUWE plans to release Q4 and full-year 2024 results on March 11, 2025. 2. A conference call to discuss results will occur at 9:00 AM ET. 3. NUWE focuses on Aquadex SmartFlow for treating fluid overload. 4. Webcast and audio archive available on NUWE's Investor page post-call.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may reveal positive growth or developments for NUWE, similar to past earnings reports boosting stock prices.

How important is it?

Earnings announcements can significantly influence stock prices, especially for companies like NUWE in a specialized market.

Why Short Term?

The financial results and associated reactions will likely impact NUWE’s stock price shortly after the announcement.

Related Companies

NUWE
February 18, 2025 16:15 ET  | Source: Nuwellis, Inc. MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year 2024 on March 11, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-245-3047 (U.S) or 1-203-518-9765 (international) and using the conference ID: NUWEQ4. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com. About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a commercial-stage medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X. About the Aquadex SmartFlow® System  The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. CONTACTS INVESTORS: Vivian CervantesGilmartin Group LLC ir@nuwellis.com

Related News